Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen P Hunger

Showing results (131-140 of 346) with videos related to

Pageof 35
Sort By:
Blood|December 13, 2012
Genome-wide study of methotrexate clearance replicates SLCO1B1Laura B Ramsey, John C Panetta, Colton Smith, et al.
Pediatric Blood & Cancer|March 4, 2015
Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2Elizabeth A Raetz, Mitchell S Cairo, Michael J Borowitz, et al.
Haematologica|April 21, 2019
Impact of corticosteroid pretreatment in pediatric patients with newly diagnosed B-lymphoblastic leukemia: a report from the Children's Oncology GroupElizabeth A Raetz, Mignon L Loh, Meenakshi Devidas, et al.
Blood|October 26, 2016
Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemiaSarah K Tasian, David T Teachey, Yong Li, et al.
Pediatric Blood & Cancer|March 2, 2011
Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906W Paul Bowman, Eric L Larsen, Meenakshi Devidas, et al.
Leukemia & Lymphoma|November 9, 2017
Severe pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trialsMichael J Burke, Meenakshi Devidas, Kelly Maloney, et al.
Pediatric Blood & Cancer|October 2, 2012
The thirteenth international childhood acute lymphoblastic leukemia workshop report: La Jolla, CA, USA, December 7-9, 2011Stephen P Hunger, Andre Baruchel, Andrea Biondi, et al.
Cancer Discovery|July 5, 2014
Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199Triona Ni Chonghaile, Justine E Roderick, Cian Glenfield, et al.
Pediatric Blood & Cancer|June 1, 2023
Minimal residual disease predicts outcomes in KMT2A-rearranged but not KMT2A-germline infant acute lymphoblastic leukemia: Report from Children's Oncology Group study AALL0631Kelly E Faulk, John A Kairalla, ZoAnn E Dreyer, et al.
Blood Advances|September 24, 2025
Age-based pegaspargase dosing is safe and achieves therapeutic levels in infants with ALL: report from COG AALL15P1Kelly E Faulk, John A Kairalla, Emily Hibbitts, et al.
Pageof 35

Showing results (131-140 of 346) with videos related to

Sort By:
Pageof 35
Blood|December 13, 2012
Genome-wide study of methotrexate clearance replicates SLCO1B1Laura B Ramsey, John C Panetta, Colton Smith, et al.
Pediatric Blood & Cancer|March 4, 2015
Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2Elizabeth A Raetz, Mitchell S Cairo, Michael J Borowitz, et al.
Haematologica|April 21, 2019
Impact of corticosteroid pretreatment in pediatric patients with newly diagnosed B-lymphoblastic leukemia: a report from the Children's Oncology GroupElizabeth A Raetz, Mignon L Loh, Meenakshi Devidas, et al.
Blood|October 26, 2016
Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemiaSarah K Tasian, David T Teachey, Yong Li, et al.
Pediatric Blood & Cancer|March 2, 2011
Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906W Paul Bowman, Eric L Larsen, Meenakshi Devidas, et al.
Leukemia & Lymphoma|November 9, 2017
Severe pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trialsMichael J Burke, Meenakshi Devidas, Kelly Maloney, et al.
Pediatric Blood & Cancer|October 2, 2012
The thirteenth international childhood acute lymphoblastic leukemia workshop report: La Jolla, CA, USA, December 7-9, 2011Stephen P Hunger, Andre Baruchel, Andrea Biondi, et al.
Cancer Discovery|July 5, 2014
Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199Triona Ni Chonghaile, Justine E Roderick, Cian Glenfield, et al.
Pediatric Blood & Cancer|June 1, 2023
Minimal residual disease predicts outcomes in KMT2A-rearranged but not KMT2A-germline infant acute lymphoblastic leukemia: Report from Children's Oncology Group study AALL0631Kelly E Faulk, John A Kairalla, ZoAnn E Dreyer, et al.
Blood Advances|September 24, 2025
Age-based pegaspargase dosing is safe and achieves therapeutic levels in infants with ALL: report from COG AALL15P1Kelly E Faulk, John A Kairalla, Emily Hibbitts, et al.
Pageof 35